A 48-Week Pilot Study Switching Suppressed Patients to Darunavir/Ritonavir and Etravirine from Enfuvirtide, Protease Inhibitor(s), and Non-nucleoside Reverse Transcriptase Inhibitor(s)
2010 ◽
Vol 26
(11)
◽
pp. 1215-1219
◽
2003 ◽
Vol 188
(10)
◽
pp. 1444-1454
◽
2016 ◽
Vol 9
(1)
◽
2007 ◽
Vol 848
(2)
◽
pp. 369-373
◽
2007 ◽
Vol 29
◽
pp. S549-S550